tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Avalo Therapeutics initiated with a Buy at BTIG

BTIG analyst Julian Harrison initiated coverage of Avalo Therapeutics (AVTX) with a Buy rating and $40 price target The firm sees the company’s AVTX-009 as having best-in-class features that could support preferred positioning in several large indications. Avalo’s lead efforts are in hidradenitis suppurativa, where BTIG continues to expect significant reward for more active treatment options, even after key IL-17A/F inhibitors are expected to be well-established, the analyst tells investors in a research note.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1